Publication | Closed Access
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
3.3K
Citations
25
References
2013
Year
In this study, which was terminated for efficacy at the prespecified interim analysis, radium-223 improved overall survival. (Funded by Algeta and Bayer HealthCare Pharmaceuticals; ALSYMPCA ClinicalTrials.gov number, NCT00699751.).
| Year | Citations | |
|---|---|---|
Page 1
Page 1